๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

II. Current National Cancer Institute center programs

โœ Scribed by William M. Roberson

Publisher
John Wiley and Sons
Year
1972
Tongue
English
Weight
185 KB
Volume
29
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Inflammatory breast carcinoma incidence
Inflammatory breast carcinoma incidence and survival : The Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975-1992
โœ Shine Chang; Sheryl L. Parker; Tuan Pham; Aman U. Buzdar; Stephen D. Hursting ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 114 KB ๐Ÿ‘ 2 views

## Background: Little is known about the cause of inflammatory breast carcinoma (ibc), the most aggressive form of breast cancer. to the authors' knowledge, no studies have investigated whether ibc risk factors are different from those for breast carcinoma overall, and there has been only one repor

Phase II study of pemetrexed disodium, a
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group
โœ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB ๐Ÿ‘ 2 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati